Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase

The approval of BRAF and MEK inhibitors has significantly improved treatment outcomes for patients with BRAF-mutated metastatic melanoma. The 3 first-line targeted therapy trials have provided similar results, and thus the identification of predictive biomarkers may generate a more precise basis for...

Descripción completa

Detalles Bibliográficos
Autores principales: GLUTSCH, Valerie, AMARAL, Teresa, GARBE, Claus, THOMS, Kai-Martin, MOHR, Peter, HAUSCHILD, Axel, SCHILLING, Bastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2020
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175049/
https://www.ncbi.nlm.nih.gov/pubmed/32449784
http://dx.doi.org/10.2340/00015555-3526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175049/
https://www.ncbi.nlm.nih.gov/pubmed/32449784
http://dx.doi.org/10.2340/00015555-3526

Ejemplares similares